Recipharm

Recipharm AB is a Swedish company, active as a pharmaceutical contract development and manufacturing organization(CDMO), with production facilities in Sweden, France, the UK and Switzerland and a development site in Sweden. Recipharm employs over 1400 people and operates nine production facilities. Its current production consists of over six hundred different products in a variety of dosage forms to global pharmaceutical companies. Recipharm is privately owned.

History

• 1995 - The company Recip was founded, by the owners Lars Backsell and Thomas Eldered, after a Management Buyout of a tablet production site owned by Pharmacia. Recip at this stage had 140 employees an 220 million SEK turnover.
• 1998 - Recip’s first CMO commissions for two major Nordic pharmaceutical companies. Tricum Fibres site in Höganäs, Sweden, was acquired.
• 2001 - The CMO brand Recipharm was established.
• 2002 - A penicillin plant in Strängnäs, Sweden, was acquired from AstraZeneca.
• 2004 - A semi solid facility in Karlskoga, Sweden, was acquired from AstraZeneca.
• 2005 - The organisation was restructured into separate subsidiaries.
• 2007 - A final decision was made, to focus only on outsourcing business. The distribution company with the Recip products was sold to Meda. A sterile facility was acquired in Monts, France, from AstraZeneca. A new development centre was obtained. A “multi-purpose” facility was acquired in Great Britain.
• 2008 - Acquisition of: Lyophilisation facility in Switzerland, A capsule production facility in Fontaine-lès-Dijon, France, The majority share of an AstraZeneca biotech laboratory in Södertälje, Sweden. About 1400 employees, turnover 1427 million SEK. The name of the company was changed from Recip to Recipharm.

External links

• Recipharm.com